Erratum to: Shaitelman SF, Anderson BM, Arthur DW, Bazan JG, Bellon JR, Bradfield L, Coles CE, Gerber NK, Kathpal M, Kim L, Laronga C, Meattini I, Nichols EM, Pierce LJ, Poppe MM, Spears PA, Vinayak S, Whelan T, Lyons JA. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2024;14:112-132.

Publikováno v: Practical radiation oncology [Pract Radiat Oncol] 2024 Nov-Dec; Vol. 14 (6), pp. 613.

Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial.

Autor: Wong JS; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Uno H; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Tramontano AC; Dana-Farber Cancer Institute, Boston, Massachusetts., Fisher L; Dana-Farber Cancer Institute, Boston, Massachusetts., Pellegrini CV; Dana-Farber Cancer Institute, Boston, Massachusetts., Abel GA; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Burstein HJ; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Chun YS; Harvard Medical School, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., King TA; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Schrag D; Memorial Sloan Kettering Cancer Center, New York, New York., Winer E; Yale Cancer Center, New Haven, Connecticut., Bellon JR; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Cheney MD; Maine Medical Center, Portland, Maine., Hardenbergh P; Vail Health, Vail, Colorado., Ho A; Duke University Medical Center, Durham, North Carolina., Horst KC; Stanford University School of Medicine, Stanford, California., Kim JN; Fred Hutchinson Cancer Center/UW Medicine, Seattle, Washington., Leonard KL; Warren Alpert Medical School of Brown University, Providence, Rhode Island.; Rhode Island Hospital, Providence., Moran MS; Yale Cancer Center, New Haven, Connecticut., Park CC; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Recht A; Harvard Medical School, Boston, Massachusetts.; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Soto DE; Massachusetts General Hospital, Boston., Shiloh RY; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Stinson SF; Johns Hopkins School of Medicine, Baltimore, Maryland., Snyder KM; Northern Light Health, Brewer, Maine., Taghian AG; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Boston., Warren LE; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Wright JL; Johns Hopkins School of Medicine, Baltimore, Maryland., Punglia RS; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Oct 01; Vol. 10 (10), pp. 1370-1378.

Clinicogenomic characterization of inflammatory breast cancer.

Autor: Priedigkeit N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Harrison B; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Shue R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Hughes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Li Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Kirkner GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Spurr LF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Remolano MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Strauss S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Files J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Feeney AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Grant L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mohammed-Abreu A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garrido-Castro A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Sousa RB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bychkovsky B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA., Nakhlis F; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Bellon JR; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA., King TA; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Lindeman N; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sholl L; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Dillon D; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Overmoyer B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Cherniack A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; The Broad Institute of MIT & Harvard, Cambridge, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA., Lynce F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 May 10. Date of Electronic Publication: 2024 May 10.

Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline.

Autor: Shaitelman SF; Department of Breast Radiation Oncology, University of Texas MD - Anderson Cancer Center, Houston, Texas. Electronic address: sfshaitelman@mdanderson.org., Anderson BM; Department of Radiation Oncology, University of Wisconsin, Madison, Wisconsin., Arthur DW; Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia., Bazan JG; Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, California., Bellon JR; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts., Bradfield L; American Society for Radiation Oncology, Arlington, Virginia., Coles CE; Department of Oncology, University of Cambridge, Cambridge, United Kingdom., Gerber NK; Department of Radiation Oncology, New York University Grossman School of Medicine, New York, New York., Kathpal M; Department of Radiation Oncology, Duke University Wake County Campus, Raleigh, North Carolina., Kim L; Department of Radiation Oncology, MD - Anderson Cancer Center at Cooper, Camden, New Jersey., Laronga C; Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida., Meattini I; Department of Radiation Oncology, University of Florence, Florence, Italy., Nichols EM; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland., Pierce LJ; Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan., Poppe MM; Department of Radiation Oncology, Huntsman Cancer Institute, Salt Lake City, Utah., Spears PA; Patient Representative, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Vinayak S; Department of Medical Oncology, University of Washington, Seattle, Washington., Whelan T; Department of Oncology, McMaster University, Hamilton, Ontario, Canada., Lyons JA; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio.

Publikováno v: Practical radiation oncology [Pract Radiat Oncol] 2024 Mar-Apr; Vol. 14 (2), pp. 112-132. Date of Electronic Publication: 2023 Nov 15.

HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.

Autor: Li Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Metzger Filho O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Viale G; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.; University of Milan, School of Medicine, Milan, Italy., dell'Orto P; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy., Russo L; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy., Goyette MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Kamat A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard University, Cambridge, Massachusetts, USA., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee, USA., Gupta Abramson V; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA., Arteaga CL; University of Texas Southwestern, Simmons Comprehensive Cancer Center, Dallas, Texas, USA., Spring LM; Department of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA., Chiotti K; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA., Halsey C; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA., Waks AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., King TA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Lester SC; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Bellon JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Winer EP; Department of Internal Medicine, Yale Cancer Center, New Haven, Connecticut, USA., Spellman PT; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA., Krop IE; Department of Internal Medicine, Yale Cancer Center, New Haven, Connecticut, USA., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Feb 01; Vol. 134 (7). Date of Electronic Publication: 2024 Feb 01.